Ivan R. Gonzalez: Interesting review of Treatment Sequences in Advanced EGFR-Mutated NSCLC
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:
An interesting review of Treatment Sequences in Advanced EGFR-Mutated NSCLC:
-TKIs have revolutionized the evolution of advanced NSCLC with common EGFR mutation.
-Tumor heterogeneity and acquired resistance mechanisms are inevitable limits.
-Recent treatment combinations show better outcomes in progression-free survival.
-These advances come with more serious side effects compared to the current standard.
-New therapeutic options open up possibilities for various treatment sequences.
-It is essential to consider the clinical and biological profile, as well as the patient’s preferences.
This review proposes an overview of published and future advances in EGFR-mutated NSCLC and a management algorithm that considers the different first-line options.”
Treatment sequences in EGFR mutant advanced NSCLC
Autors: M. Wespiser, A. Swalduz, M. Pérol
Source: Ivan R. Gonzalez/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023